Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Definity infusion

First Posted Date: 2014-04-16

Last Posted Date: 2019-12-04

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 17

Registration Number: NCT02115607

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling

Early Phase 1

Completed

Conditions: Head and Neck Squamous Cell Cancer

Interventions: Drug: Metformin

First Posted Date: 2014-03-11

Last Posted Date: 2024-02-22

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 50

Registration Number: NCT02083692

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Phase 2

Active, not recruiting

Conditions: Iris Melanoma
Stage IIA Intraocular Melanoma
Ciliary Body and Choroid Melanoma, Small Size
Stage IIIB Intraocular Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Stage IIIC Intraocular Melanoma
Stage I Uveal Melanoma AJCC V7
Stage II Uveal Melanoma AJCC V7
Stage I Intraocular Melanoma
Stage IIIA Intraocular Melanoma

Interventions: Drug: Sunitinib Malate + Valproic Acid
Drug: Valproic Acid
Drug: Sunitinib
Drug: Sunitinib Malate

First Posted Date: 2014-02-21

Last Posted Date: 2024-03-15

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 210

Registration Number: NCT02068586

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Phase 2

Completed

Conditions: Hematopoietic/Lymphoid Cancer

Interventions: Radiation: Total-Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Cyclophosphamide
Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)
Drug: Mycophenolate mofetil

First Posted Date: 2013-11-13

Last Posted Date: 2018-06-07

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 41

Registration Number: NCT01982682

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer

Phase 1

Completed

Conditions: Colon Cancer

Interventions: Biological: Ad5-hGCC-PADRE vaccine

First Posted Date: 2013-10-30

Last Posted Date: 2017-04-05

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT01972737

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Phase 1

Terminated

Conditions: Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
HER2-negative Breast Cancer
Inflammatory Breast Cancer

Interventions: Drug: Romidepsin
Drug: Abraxane

First Posted Date: 2013-09-10

Last Posted Date: 2017-12-28

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 9

Registration Number: NCT01938833

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

Phase 1

Completed

Conditions: Stage 0/1 Breast Cancer
Post Biopsy
Pre-surgery

Interventions: Drug: IV/oral n-acetylcysteine

First Posted Date: 2013-06-17

Last Posted Date: 2018-06-20

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 13

Registration Number: NCT01878695

Locations: 🇺🇸
Jefferson Myrna Brind Center for Integrative Medicine, Philadelphia, Pennsylvania, United States

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Malignant Neoplasm

Interventions: Radiation: Total-body irradiation
Biological: Donor lymphocytes infusion (DLI)
Drug: Cyclophosphamide
Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)
Drug: Tacrolimus
Drug: Mycophenolate mofetil

First Posted Date: 2013-06-06

Last Posted Date: 2018-02-08

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 4

Registration Number: NCT01871441

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Phase 2

Active, not recruiting

Conditions: Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
de Novo Myelodysplastic Syndromes
Myelodysplastic Syndrome With Isolated Del(5q)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)

Interventions: Drug: Sirolimus
Drug: Azacitidine

First Posted Date: 2013-06-05

Last Posted Date: 2024-03-13

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 57

Registration Number: NCT01869114

Locations: 🇺🇸
Jefferson Health, Aria Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Jefferson Health, Methodist Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Abington Hospital - Jefferson Health, Abington, Pennsylvania, United States

and more 2 locations

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: Alisertib
Drug: Abiraterone acetate
Drug: Prednisone

First Posted Date: 2013-05-07

Last Posted Date: 2017-12-06

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 9

Registration Number: NCT01848067

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Home Terms & Conditions Privacy Policy